Sanofi
https://www.sanofi.com//
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanofi
Long Wait Ahead For Novartis's Leqvio In US
The timeline for a US resubmission of the closely watched PCSK9-targeting cholesterol treatment could be either Q2 or Q3 and approval will depend on whether the FDA needs to make a physical inspection of an Italian facility.
Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Ablynx N.V.
- Acambis PLC
- Bioverativ Inc. (True North Therapeutics, Inc.)
- BiPar Sciences Inc.
- BMP Sunstone Corporation
- Canderm Pharma Inc.
- Chattem, Inc.
- Connaught Laboratories Ltd.
- Fisons Ltd.
- Fovea Pharmaceuticals, SA
- Genfar S.A.
- Genzyme Corporation
- Groupe Sanofi
- Hoechst Marion Roussel
- Pluromed
- Principia Biopharma Inc. Protein Sciences Corporation
- Rhone-Poulenc Rorer
- Sanofi-Aventis
- Sanofi-aventis Groupe
- Sanofi Pasteur MSD
- Shantha
- Synthorx, Inc. (THOR)
- TargeGen, Inc.
- Thunder Acquisition
- Avigen Inc.